Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy

NCT02769169 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped study protocol changed

Conditions

Polypoidal Choroidal Vasculopathy

Interventions

DRUG: Lucentis® (Raibizumab) double-dose
DRUG: Lucentis® (Raibizumab) regular-dose

Sponsor

Sun Yat-sen University